Mark Sylvester
Entasis Therapeutics (United States)(US)
Publications by Year
Research Areas
Antibiotic Resistance in Bacteria, Bacterial Genetics and Biotechnology, Computational Drug Discovery Methods, Drug Transport and Resistance Mechanisms, Antibiotics Pharmacokinetics and Efficacy
Most-Cited Works
- → Application of Fragment-Based Lead Generation to the Discovery of Novel, Cyclic Amidine β-Secretase Inhibitors with Nanomolar Potency, Cellular Activity, and High Ligand Efficiency(2007)211 cited
- → Linear Non-competitive Inhibition of Solubilized Human γ-Secretase by Pepstatin A Methylester, L685458, Sulfonamides, and Benzodiazepines(2002)145 cited
- → Rational design of a new antibiotic class for drug-resistant infections(2021)137 cited
- → Toward the Rational Design of Carbapenem Uptake in Pseudomonas aeruginosa(2015)63 cited
- → Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering(2015)62 cited
- → Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications(2014)51 cited
- → Whole-Cell-Based Assay To Evaluate Structure Permeation Relationships for Carbapenem Passage through the Pseudomonas aeruginosa Porin OprD(2017)44 cited
- → Synthesis and enzymatic evaluation of a P1 arginine aminocoumarin substrate library for trypsin-like serine proteases(2000)38 cited
- → C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl α-ketoheterocycles(2000)35 cited
- → SAR and Structural Analysis of Siderophore-Conjugated Monocarbam Inhibitors of Pseudomonas aeruginosa PBP3(2015)27 cited